Professor John R. Higgins is the Professor of Obstetrics & Gynaecology at University College Cork. He is a practicing Obstetrician & Gynaecologist at Cork University Maternity Hospital. He is the current Head of the College of Medicine & Health at UCC.
John's subspecialty clinical and research interests are in the area of Maternal Fetal medicine. He has published widely on a range of topics including pre-eclampsia (high blood pressure in pregnancy), folic acid and pregnancy, twin pregnancy, and haemostatic alterations in pregnancy. In particular, he has explored the relationship between altered haemostasis and pregnancy complications including miscarriage, pre-eclampsia, fetal growth restriction, stillbirth and placental abruption. He has co-authored the National Guideline on Prevention of Venous Thrombosis in Pregnancy (2013).
John trained initially in internal medicine (MRCPI 1991). He commenced clinical and academic training in Obstetrics & Gynaecology at the Rotunda Hospital and the TCD Department of Obstetrics & Gynaecology led by Professor John Bonnar (MRCOG 1996, MD 1996). He undertook a fellowship in Maternal Fetal medicine at the University of Melbourne Perinatal Medicine Department at the Royal Women’s Hospital Melbourne. He was appointed Senior Lecturer at the University of Melbourne and Consultant Obstetrician & Gynaecologist at the Mercy Hospital for Women in 2000.
John returned to Ireland to take up the UCC Chair in Obstetrics & Gynaecology in 2001.
Prior to this, Colman was the administrative director for research and industrial liaison of the College of Medicine and Health and the interim director of the Cork Science and Innovation Park in University College Cork. During this time, he was also the president and one of the founder members of PDA Ireland.
He spent seven years as general manager of an FDA/EMEA regulated multinational biotech, ten years in line management in a pharmaceutical manufacturing environment and has seven years experience in enzyme production for the food industry. Colman served on the boards of Avecia, ISPE, American Chamber of Commerce, National Food Biotechnology Centre and Cork University Foundation and was granted a Distinguished Alumnus Award by University College Cork in 2003.
Tanya joined the Health Innovation Hub in December 2013. She has a wealth of experience in the public and private sector; her most recent role was Manager of the College of Science, Engineering and Food Science, UCC. She has an honours degree in Biochemistry and a PhD in Cancer Genetics from UCC.
She has conducted postdoctoral research in population based Neuropsychiatric Genetics at Trinity College Dublin and has over 10 years’ experience in biotechnology based research and development industries – Schering Plough (NJ, USA) and start-up Biotechnology company Orchid Biosciences (Princeton, NJ). Dr Mulcahy returned to Ireland from the USA in 2006 and worked with Science Foundation Ireland before joining UCC in 2009.
Tanya is a member of the Executive Management Board of Eureka Centre for inquiry based Education in Science and Mathematics. She is co-ordinator of the BioInnovate programme at UCC.
Before joining the HIH Team in 2014 as Research Support Officer, Gillian has had a wealth of experience working in an administrative capacity in diverse areas including legal, engineering and medical services. She graduated UCC with a BA Honours Degree in languages. She lived in the US for ten years before returning to Cork in 2002.
Joe Eustace, Professor of Medicine, Consultant Nephrologist and the Director of the Clinical Research Facility, Cork. Professor Eustace graduated from University College Dublin in 1990, undertook postgraduate training in General Internal Medicine and Nephrology in Dublin and from 1996-1999 he undertook a Clinical Nephrology Fellowship in Johns Hopkins University Hospital, Baltimore; and a NIH Fellowship in Clinical Epidemiology at the Bloomberg School of Public Health as part of which he completed a MHS degree. He was subsequently appointed to the Johns Hopkins Faculty of Medicine and Clinical Epidemiology as an Assistant Professor and while at Hopkins served as Director of Ambulatory Dialysis Services and as State Commissioner in the Maryland Kidney Commission. He returned to Ireland to take up the position of Consultant Nephrologist at Cork University Hospital in 2005 and was appointed Professor and Director of the HRB Clinical Research Facility at UCC in 2011. His research has been funded by the NIH (NIDDK), National Kidney Foundation, Johns Hopkins Clinical Scientist Award and the Health Research Board. He has authored or co-authored over 45 peer reviewed original scientific papers, and written 8 book chapters. His current research focus is on Vascular and Bone Health in Renal Transplant Recipients.
Mark Bruzzi is a Professor in Biomedical Engineering at the National University of Ireland Galway and is also the Director and co-founder of the BioInnovate Ireland medical device innovation programme. BioInnovate Ireland is a multidisciplinary programme focusing on medical device product development from clinical needs identification, market validation, prototype development and business planning. Mark also is supporting the development of a number of innovative medical technologies He has over 50 journal and conference publications, seven patent applications, 3 licensed technologies and serves as an advisor to several medical device start-ups.
Dr Michael Conall Dennedy is a Consultant Endocrinologist at Galway University Hospital and a Senior Lecturer in Therapeutics at NUI, Galway.
He is a Galway graduate, completing a BSc in Pharmacology in 2000, MB, BAO, BCh in 2002, MD in Obstetrics in 2007 and PhD in Medicine in 2013. He trained through the HSE/HRB National SpR Academic Fellowship Programme, an integrated academic clinician scientist programme. Following this he completed a fellowship in endocrinology at the University of Cambridge and Addenbrooke's hospital. He assumed his current post in February 2014.
His research interests centre on the pathogenesis and treatment of functional adrenal tumours, both benign and malignant. He is a member of the European Network for the Study of Adrenal Tumour working Groups for Adrenocortical Carcinoma, Aldosterone Producing Adenomas, Phaeochromocytoma and Non Aldosterone Producing Adrenocortical Adenomas. He retains links with the Institute of Metabolic Science, University of Cambridge and has forged collaborations with the Centre for Endocrinology, Diabetes and Metabolism, University of Birmingham. He is also affiliated with the CURAM programme at NUI, Galway and the Translational Medical Device Laboratory.
He is the NUI, Galway director for the Wellcome/HRB Irish Clinical Academic Training (ICAT) Programme and a co-recepient of this award. He is also the director of the undergraduate MB/PhD programme at NUI, Galway. He is the Specialty Director for Endocrinology for the Royal College of Physicians of Ireland's, International Clinical Fellows Programme.
Martin O’Donnell is the Professor of Translational Medicine at NUI Galway and Interim Director of the CRFG. Graduated from University College Cork, he trained in Geriatric and Stroke medicine in Ireland, McMaster University (Canada) and Stanford University (US). He holds a PhD from the Department of Clinical Epidemiology and Biostatistics, McMaster University. He is Director of the MSc in Clinical Research at NUIG, being run in collaboration with McMaster University.
His main areas of research interest are in Vascular medicine and Stroke Epidemiology.
Prof. Timothy O’Brien is professor and chair of Medicine and Director of REMEDI at the National University of Ireland (NUI) Galway. He is consultant physician in Endocrinology and Dean of the College of Medicine, Nursing & Health Sciences at the NUI Galway.
Prof. Timothy O’Brien trained in internal medicine and endocrinology in Cork, Milwaukee, Rochester and San Francisco. Prior to joining NUI Galway, he worked at Medical College of Wisconsin in Milwaukee, the Mayo Clinic in Rochester, Minnesota and the Gladstone Institute of Cardiovascular Disease at the University of California, San Francisco. In 2001 he was appointed as Head of Medicine at NUI Galway and Consultant Endocrinologist at Galway University Hospital. In 2004 he established the Regenerative Medicine Institute (REMEDI) at NUI Galway with funding from Science Foundation Ireland and currently holds the position of Director.
Research interests include the translation of basic research findings in stem cell biology to regenerative approaches to peripheral vascular disease and diabetic complications in partnership with industry and the health service. He has an active research group at REMEDI NUI Galway investigating the use of mesenchymal stromal cells and endothelial progenitor cells in vascular complications of diabetes mellitus. He is Director of the GMP cell manufacturing facility at NUI Galway and has been a PI on gene therapy and cell therapy clinical trials in Galway. In addition to a laboratory-based programme, his research brings together the Galway HRB Clinical Research Facility, the Galway Blood and Tissue Establishment and the Centre for Cell Manufacturing Ireland for translational research in stem cells and gene therapy.
Professor O’Brien is coordinator of 2 current EU funded projects; EU FP7 REDDSTAR which is developing and testing a novel stromal cell therapy to treat complications of diabetes mellitus and the recently started EU H2020 NEPHSTROM, which will clinically validate a novel stromal cell therapy for the stabilization of progressive diabetic kidney disease.
Prof. O’Brien has published an average of 15 manuscripts per year over the past 5 years.
Prof. O’Brien has a total of 254 publications; with 103 Senior Author Publications; 174 Journal Articles; 80 Reviews and 21 Book Chapters.
Dr Martin O'Halloran is a European Research Council (ERC) and Science Foundation Ireland (SFI) Investigator at the National University of Ireland Galway. Reflecting the interdisciplinary nature of his research, he holds a joint affiliation with the College of Engineering and Informatics; and the College of Medicine, Nursing & Health Sciences, and leads the Translational Medical Device Laboratory in the Lambe Institute.
Dr O'Halloran has received over 20 national and international research awards, and was recently awarded NUI Galway's Early-Stage Researcher of the Year, Engineers Ireland Chartered Engineer of the Year, and the European Research Council's Starting Investigator Grant. He was a co-proposer of a European COST Action (entitled "MiMED"), and is now leading a network of over 180 medical device researchers from 24 countries, focused on the clinical evaluation and commercialisation of novel medical devices in Europe.
Over the last 6 years, Dr O'Halloran has personally secured €3.28 million in direct research funding and has published more than 40 papers in peer-reviewed journals, and a similar number of international conference papers. Dr O'Halloran has been an invited chair and invited speaker at several major electromagnetics and translational medicine conferences/seminars. He is currently on the steering committee of the BioInnovate programme, and is the Director of Enabling Technologies.
Professor Seamas Donnelly is Professor of Medicine and Dean of Research at the School of Medicine, Trinity College Dublin. He has a long standing interest in Connected Health and in particular evaluating early stage technologies with regards to assessing quality of life of patients remotely.
He has generated over €40 million in grant funding since returning to Ireland and has recently been awarded an honorary Professorship from the University of Edinburgh for international leadership in Translational Medicine. He is currently an SFI Investigator Programme grant holder and leads the Precision Medicine initiative within Trinity College Dublin.
Professor Michael Gill (MD, MRCPsych FTCD) is Professor of Psychiatry and Head of Discipline at Trinity College Dublin and Consultant Psychiatrist at St James’ Hospital. He leads the Neuropsychiatric Genetics Research Group which conducts ongoing Phenotypic and Genomic investigations into Autism, Psychosis and ADHD. The goal of this research is to identify and investigate the function of genetic variation contributing to disease risk as a means of improving understanding of disease biology, developing better methods of diagnosis, and establishing new therapeutic approaches. The group has played a significant role in large collaborative genomics studies and has been part of several significant discoveries in recent years published in journals such as Nature, Nature Genetics, Archives of General Psychiatry and the British and American Journals of Psychiatry. In 2012 he was appointed as Director and Principle Investigator of the Dublin Centre for Clinical Research that includes the network of four CRFs at TCD, UCD and RCSI and the Wellcome Trust Clinical Research Facility at St. James’ Hospital which opened in 2013 and after two years in operation has over 80 studies on its books. He is Co-Director of the recently funded HRB Clinical Research Coordination Ireland, supporting coordinated multisite clinical trials in Ireland; Executive committee member of the HRB Trials Methodology Research Network and the TCD lead in the National Health Innovation Hub. He is a Board member of the Trinity College Institute of Neuroscience and of Molecular Medicine Ireland.
Dan is a health innovation advisor to the HIH, TCD. He is founder of innovation management company Nua Venture and has held multiple CEO, R&D, Operations & Marketing roles across a wide range of medical and information technology companies including Hemanua (Ireland), Hemacon (Düsseldorf & Bangalore), Biomedical Research Limited (Ireland), Medinet (New York), Siemens (Munich), and Digital Equipment Corporation (Boston & Sophia Antipolis). He holds two patents in neuromuscular stimulation. In addition, as former Head of Technology Strategy at ACT Venture Capital, he has been a board member in a wide range of early-stage technology companies including AEP Networks Ltd. (Chairman), Cappella Inc. (Vice-Chair), Amphion Ltd (Director), Heartsine Inc. (Director) and Innovada Ltd. (Chairman). Dan holds an M.Eng.Sc in Electronic Engineering from University College Dublin and an MBA from INSEAD in France.